HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    
What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


BIO: Bio Rad Laboratories Cl A - Full Company Report Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Full Company Report |  Estimates |  Brokerage Recommendations |  Comparison to Industry |  Insiders |  Brokerage Reports |  Zacks Equity Research   |  Annual Report
BIO RAD LABORATORIES CL A (NYSE)
BIO 100.35 0.84 (0.84%) Vol.  40,574 16:01 ET
Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California.

 General Information
BIO-RAD LABS -A
1000 Alfred Nobel Drive
Hercules, CA 94547
Phone: 510 724-7000
Fax: 510 724-3167
Web: www.bio-rad.com
Email: investor_relations@bio-rad.com.
 
Industry MED PRODUCTS
Sector: Medical
 
Fiscal Year End December
Last Reported Quarter 09/30/09
Next EPS Date 02/25/2010
 
 Price and Volume Information
Zacks Rank
Yesterday's Close 99.51
52 Week High 100.99
52 Week Low 51.33
Beta 1.07
20 Day Moving Average 67,918.50
Target Price Consensus 104.25
 
 % Price Change
4 Week 8.75
12 Week 16.09
YTD 32.13
 % Price Change Relative to S&P 500
4 Week 4.60
12 Week 4.79
YTD 7.18
 Share Information
Shares Outstanding (millions) 27.42
Market Capitalization (millions) 2,728.17
Short Ratio 3.72
Last Split Date 03/08/2002
 Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

 EPS Information
Current Quarter EPS Consensus Estimate 1.02
Current Year EPS Consensus Estimate 4.62
Estimated Long-Term EPS Growth Rate 11.30
Next EPS Report Date 02/25/2010
 Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell) 1.50
30 Days Ago 1.67
60 Days Ago 1.67
90 Days Ago 1.50

 Fundamental Ratios
 P/E
Current FY Estimate: 21.52
Trailing 12 Months: 19.78
PEG Ratio 1.91
 EPS Growth
vs. Previous Year 36.63%
vs. Previous Quarter 0.73%
 Sales Growth
vs. Previous Year 4.35%
vs. Previous Quarter: 7.93%
 Price Ratios
Price/Book 2.22
Price/Cash Flow 20.94
Price / Sales 1.57
 ROE
09/30/09 12.46
06/30/09 11.98
03/31/09 12.52
 ROA
09/30/09 6.30
06/30/09 6.13
03/31/09 6.59
 Current Ratio
09/30/09 3.62
06/30/09 3.64
03/31/09 2.95
 Quick Ratio
09/30/09 2.69
06/30/09 2.66
03/31/09 1.91
 Operating Margin
09/30/09 7.99
06/30/09 7.45
03/31/09 7.66
 Net Margin
09/30/09 8.51
06/30/09 8.15
03/31/09 8.42
 Pre-Tax Margin
09/30/09 8.51
06/30/09 8.15
03/31/09 8.42
 Book Value
09/30/09 44.78
06/30/09 41.21
03/31/09 38.74
 Inventory Turnover
09/30/09 2.02
06/30/09 2.02
03/31/09 2.06
 Debt-to-Equity
09/30/09 0.60
06/30/09 0.65
03/31/09 0.42
 Debt to Capital
09/30/09 37.57
06/30/09 39.57
03/31/09 29.56

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research